A comparative planning study of step-and-shoot IMRT versus helical tomotherapy for whole-pelvis irradiation in cervical cancer
Chitapanarux I, Tharavichitkul E, Nobnop W, Wanwilairat S, Vongtama R, Traisathit P | J Radiat Res | 2015
Safety of adjuvant intensity-modulated postoperative radiation therapy in endometrial cancer: Clinical data and dosimetric parameters according to the International Commission on Radiation Units (ICRU) 83 report
Cordoba A, Nickers P, Tresch E, Castelain B, Leblanc E, Narducci F, Le Tinier F, Lesoin A, Lacornerie T, Lartigau E | Rep Pract Oncol Radiother | 2015
Adjuvant intensity modulated whole-abdominal radiation therapy for high-risk patients with ovarian cancer FIGO stage III: final results of a prospective phase 2 study
Arians N, Kieser M, Benner L, Rochet N, Schröder L, Katayama S, Herfarth K, Schubert K, Schneeweiss A, Sohn C, Lindel K, Debus J | Radiat Oncol | 2019
Comparing efficacy of high-dose rate brachytherapy versus helical tomotherapy in the treatment of cervical cancer
Kim S, Lee S, Hong JH, Park YJ, Song JY, Lee JK, Lee NW | J Gynecol Oncol | 2020
Treatment Outcome of the Combination Therapy of High-dose rate Intracavitary Brachytherapy and Intensity-modulated Radiation Therapy With Central-shielding for Cervical Cancer
Mukai Y, Minagawa Y, Inoue H, Sato A, Matsui K, Fukuda T, Onuma K, Hongo H, Shirata R, Nagata H, Hashimoto H, Inoue T, Hata M, Omura M | In Vivo | 2020
Post-operative small pelvic intensity-modulated radiation therapy for early-stage cervical cancer with intermediate-risk factors: efficacy and toxicity
Zhang G, He F, Miao L, Wu H, Zhang Y, Fu C | Jpn J Clin Oncol | 2021
Efficacy of helical tomotherapy combined with CT-guided three-dimensional intracavitary brachytherapy in treatment of locally advanced cervical cancer
Ye X, Ye P, Zheng Y, Xia W | J BUON | 2021
The prognostic significance of pretreatment squamous cell carcinoma antigen levels in cervical cancer patients treated by concurrent chemoradiation therapy and a comparison of dosimetric outcomes and clinical toxicities between tomotherapy and volumetric modulated arc therapy
Cheng YK, Kuo SH, Yen HH, Wu JH, Chen YC, and Huang MY | Radiat Oncol | 2022
Comparing dosimetric and cancer control outcomes after intensity-modulated radiation therapy and tomotherapy for advanced cervical cancer – PubMed (nih.gov)
Li D, Wang D, Feng S, Chen Q, Sheng X, Jia J, Yan X, Zhu J, and Yin Y | Oncol Lett | 2022
High-dose radiotherapy with helical tomotherapy and long-term androgen deprivation therapy for prostate cancer: 5-year outcomes
Tomita N, Soga N, Ogura Y, Hayashi N, Kageyama T, Ito M, Koide Y, Yoshida M, Kimura K, Makita C, Tachibana H, Kodaira T | J Cancer Res Clin Oncol | 2016
Moderate Hypofractionation with Simultaneous Integrated Boost in Prostate Cancer: Long-term Results of a Phase I-II Study
Di Muzio NG, Fodor A, Noris Chiorda B, Broggi S, Mangili P, Valdagni R, Dell’Oca I, Pasetti M, Deantoni CL, Chiara A, Berardi G, Briganti A, Calandrino R, Cozzarini C, Fiorino C | Clin Oncol | 2016
High-Dose-Rate Brachytherapy Monotherapy versus Image-Guided Intensity-Modulated Radiotherapy with Helical Tomotherapy for Patients with Localized Prostate Cancer
Yamazaki H, Masui K, Suzuki G, Nakamura S, Shimizu D, Nishikawa T, Okabe H, Yoshida K, Kotsuma T, Tanaka E, Otani K, Yoshioka Y, Ogawa K | Cancers (Basel) | 2018
Intensity-Modulated Radiation Therapy with Simultaneous Integrated Boost for Clinically Node-Positive Prostate Cancer: A Single-Institutional Retrospective Study
Onishi M, Kawamura H, Murata K, Inoue T, Murata H, Takakusagi Y, Okonogi N, Ohkubo Y, Okamoto M, Kaminuma T, Sekihara T, Nakano T, Ohno T | Cancers (Basel) | 2021
Post-operative hypofractionated radiotherapy for prostate cancer: a mono-institutional analysis of toxicity and clinical outcomes
Ferrera G, D’Alessandro S, Cuccia F, Serretta V, Trapani G, Savoca G, Mortellaro G, Lo Casto A | J Cancer Res Clin Oncol | 2022
Moderate Hypofractionated Helical TomoTherapy for Older Patients with Localized Prostate Cancer: Long-term Outcomes of a Phase I-II Trial
Cui D, Du L, Yu W, Cai B, Meng L, Yang J, Luo Y, Chen J, and Ma L | Radiol Oncol| 2022
Adaptive Radiotherapy for Carcinoma of the Urinary Bladder: Long-term Outcomes With Dose Escalation
Murthy V, Gupta P, Baruah K, Krishnatry R, Joshi A, Prabhash K, Noronha V, Menon S, Pal M, Prakash G, Bakshi G | Clin Oncol | 2019
Ultra-hypofractionated radiation therapy for unfavourable intermediate-risk and high-risk prostate cancer is safe and effective: 5-year outcomes of a phase II trial
Macias VA, Barrera-Mellado I | BJU Int | 2020
Phase I Trial of Carboplatin and Gemcitabine Chemotherapy and Stereotactic Ablative Radiosurgery for the Palliative Treatment of Persistent or Recurrent Gynecologic Cancer
Kunos CA, Sherertz TM, Mislmani M, Ellis RJ, Lo SS, Waggoner SE, Zanotti KM, Herrmann K, Debernardo RL | Front Oncol | 2015
Stereotactic Body Radiotherapy for Recurrent or Oligometastatic Uterine Cervix Cancer: A Cooperative Study of the Korean Radiation Oncology Group (KROG 14-11)
Park HJ, Chang AR, Seo Y, Cho CK, Jang WI, Kim MS, Choi C | Anticancer Res | 2015
Stereotactic Radiotherapy in the Retreatment of Recurrent Cervical Cancers, Assessment of Toxicity, and Treatment Response: Initial Results and Literature Review
Pontoriero A, Iatì G, Aiello D, Pergolizzi S | Technol Cancer Res Treat | 2016
